Glucagon receptor activation drives energy expenditure and thermogenesis, allowing researchers to study both energy intake suppression and active caloric expenditure simultaneously a mechanistic capability not available with GIP/GLP-1 dual agonists or GLP-1 mono agonists
According to the UK Summary of Product Characteristics (SmPC), nausea occurred in approximately 1221% of patients receiving dulaglutide in the AWARD clinical trial programme, compared with higher rates observed with some other agents
Emerging evidence supports this approach
Combining ketogenic diets with prescription GLP-1 agonists requires careful medical supervision due to increased risks of hypoglycemia and diabetic ketoacidosis, particularly in patients with diabetes taking insulin or sulfonylureas
5mg vial reconstitution chart A 5mg vial is ideal for researchers starting at lower doses who want minimal waste
Wegovy mimics one hormone (GLP-1), while retatrutide mimics three (GLP-1, GIP and glucagon)
